The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.
The anti-inflammatory effect of adenosine was previously found to be mediated via activation of the A3 adenosine receptor (A3AR). The aim of the present study was to decipher the molecular mechanism involved with the inhibitory effect of IB-MECA, an A3AR agonist, on adjuvant-induced arthritis. The adjuvant-induced arthritis rats responded to IB-MECA treatment with a decrease in the clinical score and the pathological score of the disease. The response to IB-MECA was neutralized by the antagonist MRS 1220, confirming that the efficacy of the synthetic agonist was A3AR mediated. The A3AR protein expression level was highly expressed in the synovia, in the peripheral blood mononuclear cells and in the drain lymph node (DLN) tissues of adjuvant-induced arthritis rats in comparison with naïve animals. Downregulation of A3AR expression was noted upon treatment with IB-MECA. Analysis of synovia and DLN protein extracts revealed a decreased expression level of PI3K, PKB/Akt, IKK, NF-kappaB and tumor necrosis factor alpha, known to affect survival and apoptosis of inflammatory cells, whereas the caspase-3 level was upregulated.Taken together, high A3AR expression is found in the synovia, in the immune cells in the DLN and in peripheral blood mononuclear cells. IB-MECA, an orally bioavailable molecule, activates the A3AR, inducing receptor downregulation and the initiation of a molecular mechanism that involves de-regulation of the PI3K-NF-kappaB signaling pathway. As a result, a potent anti-inflammatory effect manifested in the improvement of the disease clinical score and pathological score occurs. The finding that the A3AR expression level in the peripheral blood mononuclear cells and in the DLN reflects the receptor status in the remote inflammatory site suggests use of the A3AR as a follow-up biomarker.
Fishman
Pnina
P
Can-Fite BioPharma Ltd, Kiryat-Matalon, Petah-Tikva, Israel. pnina@canfite.co.il
Bar-Yehuda
Sara
S
Madi
Lea
L
Rath-Wolfson
Lea
L
Ochaion
Avivit
A
Cohen
Shira
S
Baharav
Ehud
E
D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058918:Adenosine A3 Receptor Antagonists; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D009000:Monocytes / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D051381:Rats; D011917:Rats, Inbred Lew; D012720:Severity of Illness Index; D015398:Signal Transduction; D013583:Synovial Membrane / Q000378:metabolism / Q000473:pathology
D058918:Adenosine A3 Receptor Antagonists; D000893:Anti-Inflammatory Agents; D047908:Intracellular Signaling Peptides and Proteins; D016328:NF-kappa B; C084956:N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; D019869:Phosphatidylinositol 3-Kinases; D000241:Adenosine